Arcellx (ACLX) Depreciation & Amortization (CF) (2021 - 2025)
Arcellx's quarterly Depreciation & Amortization (CF) came in at $1.6 million in Q4 2025, down 8.27% year-on-year from $1.8 million in Q4 2024, and down 10.96% quarter-over-quarter from $1.8 million in Q3 2025.
Arcellx has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $1.6 million in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 8.27% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $6.7 million (up 28.72% YoY), and the FY2025 full-year result was $6.7 million, up 28.72% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $1.6 million, down from $1.8 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.8 million in Q3 2025, with the low at $207000.0 in Q1 2021.
- Average Depreciation & Amortization (CF) over 5 years is $813400.0, with a median of $443000.0 recorded in 2023.
- Year-over-year, Depreciation & Amortization (CF) soared 198.43% in 2024 and slipped 8.27% in 2025.
- Tracing ACLX's Depreciation & Amortization (CF) over 5 years: stood at $331000.0 in 2021, then advanced by 25.68% to $416000.0 in 2022, then jumped by 73.56% to $722000.0 in 2023, then soared by 147.78% to $1.8 million in 2024, then dropped by 8.27% to $1.6 million in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.64 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 826,000.00 |
| Mar 31, 2024 | 826,000.00 |
| Dec 31, 2023 | 722,000.00 |
| Dec 31, 2023 | 722,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Jun 30, 2023 | 439,000.00 |
| Jun 30, 2023 | 439,000.00 |
| Mar 31, 2023 | 432,000.00 |
| Mar 31, 2023 | 432,000.00 |
| Dec 31, 2022 | 416,000.00 |
| Dec 31, 2022 | 416,000.00 |
| Sep 30, 2022 | 340,000.00 |
| Sep 30, 2022 | 340,000.00 |
| Jun 30, 2022 | 302,000.00 |
| Jun 30, 2022 | 302,000.00 |
| Mar 31, 2022 | 263,000.00 |
| Mar 31, 2022 | 263,000.00 |
| Dec 31, 2021 | 331,000.00 |
| Dec 31, 2021 | 331,000.00 |
| Sep 30, 2021 | 253,000.00 |
| Sep 30, 2021 | 253,000.00 |
| Jun 30, 2021 | 250,000.00 |
| Jun 30, 2021 | 250,000.00 |
| Mar 31, 2021 | 207,000.00 |
| Mar 31, 2021 | 207,000.00 |